SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2026
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company has evaluated subsequent events through August 14, 2026, which is the date the financial statements were issued. Knight Therapeutics Inc. Share Conversion On July 22, 2026, the Company converted 8,400 shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into 658,629 shares of common stock. July 2026 Offering On July 30, 2026, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a PIPE public offering, 191,571 shares of common stock at a purchase price of $1.74 per share and 383,142 pre-funded warrants at a purchase price of $1.739 per pre-funded warrant. The investors also received Series A warrants to purchase up to 574,713 shares of common stock (the "Series A Warrants") and Series B warrants to purchase up to 574,713 shares of common stock (the "Series B Warrants" and together with the Series A Warrants, the "Warrants"). The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately until exercised in full. The Series A Warrants have an exercise price of $1.74 per share and are exercisable immediately upon issuance until the fifth anniversary of the effective date of the registration statement covering the resale of the shares issuable upon exercise of the Warrants. The Series B Warrants have an exercise price of $1.74 per share and are exercisable until the twenty-four month anniversary of the effective date of the registration statement covering the resale of the shares issuable upon exercise of the Warrants As compensation for acting as placement agent for the offering, the Company also issued to H.C. Wainwright & Co., LLC warrants to purchase up to 43,103 shares of common stock. These placement agent warrants have an exercise price of $2.175 per share, are exercisable immediately upon issuance and expire five years from the date of issuance. Concurrently with the offering, the Company entered into a Registration Rights Agreement pursuant to which the Company agreed to file a registration statement covering the resale of the shares of common stock and shares issuable upon exercise of the warrants issued in the offering. The offering closed on July 31, 2026 and resulted in gross proceeds of approximately $999,809 and net proceeds to the Company of approximately $739,809, after deducting placement agent fees and other offering expenses payable by the Company. Issuance of Shares of Common Stock On July 23, 2026, pursuant to the consulting agreement described in Note 11, the Company issued 7,500 shares of common stock to the consultant in settlement of RSUs granted in May, June and July 2026. There have been no other events or transactions during this time which would have a material effect on these consolidated condensed financial statements.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2026

13. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through August 14, 2026, which is the date the financial statements were issued.

Knight Therapeutics Inc. Share Conversion

On July 22, 2026, the Company converted 8,400 shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into 658,629 shares of common stock.

July 2026 Offering

On July 30, 2026, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a PIPE public offering, 191,571 shares of common stock at a purchase price of $1.74 per share and 383,142 pre-funded warrants at a purchase price of $1.739 per pre-funded warrant. The investors also received Series A warrants to purchase up to 574,713 shares of common stock (the "Series A Warrants") and Series B warrants to purchase up to 574,713 shares of common stock (the "Series B Warrants" and together with the Series A Warrants, the "Warrants"). The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately until exercised in full. The Series A Warrants have an exercise price of $1.74 per share and are exercisable immediately upon issuance until the fifth anniversary of the effective date of the registration statement covering the resale of the shares issuable upon exercise of the Warrants. The Series B Warrants have an exercise price of $1.74 per share and are exercisable until the twenty-four month anniversary of the effective date of the registration statement covering the resale of the shares issuable upon exercise of the Warrants

As compensation for acting as placement agent for the offering, the Company also issued to H.C. Wainwright & Co., LLC warrants to purchase up to 43,103 shares of common stock. These placement agent warrants have an exercise price of $2.175 per share, are exercisable immediately upon issuance and expire five years from the date of issuance.

Concurrently with the offering, the Company entered into a Registration Rights Agreement pursuant to which the Company agreed to file a registration statement covering the resale of the shares of common stock and shares issuable upon exercise of the warrants issued in the offering.

The offering closed on July 31, 2026 and resulted in gross proceeds of approximately $999,809 and net proceeds to the Company of approximately $739,809, after deducting placement agent fees and other offering expenses payable by the Company.

Issuance of Shares of Common Stock

On July 23, 2026, pursuant to the consulting agreement described in Note 11, the Company issued 7,500 shares of common stock to the consultant in settlement of RSUs granted in May, June and July 2026.

There have been no other events or transactions during this time which would have a material effect on these consolidated condensed financial statements.